By vgreene, 28 October, 2021 Treatment With Hydroxychloroquine Azithromycin and Combination in Patients Hospitalized With COVID 19 full text Int J Infect Dis article
By vgreene, 28 October, 2021 Association of Treatment With Hydroxychloroquine or Azithromycin With In Hospital Mortality in Patients With COVID 19 in New York State full text JAMA article
By vgreene, 28 October, 2021 Azithromycin in Addition to Standard of Care Versus Standard of Care Alone in the Treatment of Patients Admitted to the Hospital With Severe COVID 19 in Brazil COALITION II A Randomised Clinical Trial full text Lancet article
By vgreene, 28 October, 2021 Hydroxychloroquine in Patients With Mainly Mild to Moderate Coronavirus Disease 2019 An Open label Randomised Controlled Trial full text BMJ article
By vgreene, 28 October, 2021 No significant difference in clinical status at 14 days adjusted OR 1 02 95 CI 0 73 1 42 no significant difference in death rate at 28 days adjust OR 1 07 95 CI 0 54 2 09
By vgreene, 28 October, 2021 Multicenter blinded RCT 479 hospitalized pts median age 57y w severe dz received HCQ 400 mg bid x1 day then 200 mg bid x4 days n 242 vs placebo n 237 median sx duration 5 days pts also received RDV 21 7 AZ 19 CS 18 4
By vgreene, 28 October, 2021 Study considerations terminated early due to low enrollment included pts w respiratory sx for up to 10 days f u limited to 28 days no eval for viral shedding inflammatory biomarkers effect of other tx
By vgreene, 28 October, 2021 KEY FINDINGS HCQ did not significantly improve clinical status at day 14 vs placebo
